PTC Therapeutics discontinues development of ALS drug after trial failure
PTC Therapeutics said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it failed to slow disease progression in a mid-stage trial. This marks the latest setback in a long list of roadblocks on the path to developing effective treatments against amyotrophic lateral sclerosis (ALS),